Paralysis News and Research

RSS

Paralysis is the loss of muscle function in part of your body. It happens when something goes wrong with the way messages pass between your brain and muscles. Paralysis can be complete or partial. It can occur on one or both sides of your body. It can also occur in just one area, or it can be widespread. Paralysis of the lower half of your body, including both legs, is called paraplegia. Paralysis of the arms and legs is quadriplegia.

Research suggests targeting spleen may promote healing of spinal cord injury

The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.

16 Nov 2010

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

StemCells, Inc. announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC® purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.

15 Nov 2010

U.N. agencies, Rotary International launch mass polio immunization campaign in Central Africa

The WHO, UNICEF and Rotary International on Thursday announced they will kick off a "mass polio immunization campaign in three Central African nations" on Friday "in response to a polio outbreak suspected in more than 100 deaths and deemed 'unusual' because it targets adults more than children," the Associated Press reports.

14 Nov 2010

GPI launches new advocacy coalition to advance embryonic stem cell research in U.S.

The Genetics Policy Institute (GPI) today announced the launch of a new advocacy coalition of 30 organizations to foster public awareness and advance the cause of embryonic stem cell research in the United States.

12 Nov 2010

Collapsing with laughter: Literally

Dr. Claire Allen, 35, suffers from rare and severe form of sleeping sickness that makes her pass out 100 times in a day. She is a research scientist at the British Antarctic Survey and she said that she has suffered from cataplexy, a severe form of narcolepsy that sees her lose control of her body and collapse into a deep sleep – although she remains conscious throughout.

3 Nov 2010

Clear guidelines needed for consistent diagnosis and treatment of childhood stroke

Researchers are calling for clear guidelines on childhood stroke after a study, published in the November issue of Acta Paediatrica, found wide variations in time lag to diagnosis, investigation and treatment.

1 Nov 2010

Scientists develop new method to analyze early detection of virus

The virus, called enterovirus 71, is closely related to poliovirus, and was first detected in California in the 1960s. Since then the virus has spread across Asia, affecting mostly children and some adults. Serious cases of the disease can include neurological disorders such as meningitis, paralysis and encephalitis.

29 Oct 2010

Athletic performance can improve after heat acclimation

Turning up the heat might be the best thing for athletes competing in cool weather, according to a new study by human physiology researchers at the University of Oregon.

26 Oct 2010

Salk discovers potential new target for MS

Scientists are closer to solving one of the many mysteries of multiple sclerosis and other demyelinating diseases, thanks to a recent study conducted at the Salk Institute for Biological Studies. The research revealed a previously unknown connection between two ion channels, which, when misaligned, can cause the many bizarre symptoms that characterize the condition.

26 Oct 2010

Nanotope enters agreement with Smith & Nephew to develop cartilage regeneration product

Arrowhead Research Corporation today announced that its portfolio company, Nanotope, Inc., has entered into an agreement with Smith & Nephew, Inc., a member of the Smith & Nephew plc group to develop a cartilage regeneration product for human healthcare markets using a subset of its proprietary regenerative medicine technology.

18 Oct 2010

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Genentech, Inc., a member of the Roche Group, and Biogen Idec today announced 24-week results from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. Ocrelizumab demonstrated a significant reduction in disease activity as measured by brain lesions and relapse rate.

15 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

'Keyhole' procedure safer than invasive approaches in removing acoustic neuroma without hearing loss

Results from a newly released 9-year study is bringing newfound hope to the approximately 3,000 Americans diagnosed each year with acoustic neuromas (AN), little-known brain tumors that can have devastating and even fatal consequences for sufferers.

14 Oct 2010

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

Kennedy Krieger Institute announced today the launch of a first‐of‐its‐kind, phase II clinical trial to investigate a treatment for heart disease in individuals with Duchenne muscular dystrophy (DMD).

13 Oct 2010

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

Geron Corporation today announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) Impairment Scale grade A thoracic spinal cord injuries. Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.

11 Oct 2010

FDA designates NeuRx Diaphragm Pacing System as HUD device for ALS patients

Synapse Biomedical Inc. announces today that they have received the U.S. Food and Drug Administration (FDA) designation of the NeuRx Diaphragm Pacing System (DPS) as a Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis (ALS) patients with a stimulatable diaphragm who are experiencing chronic hypoventilation and has now submitted for Humanitarian Device Exemption (HDE) approval.

11 Oct 2010

Two-day symposium marks an extraordinary decade for Brown Institute for Brain Science

Just as intense concentration allows a sharp mind to perform at its peak, a research institute that concentrates pre-eminent scientists from 11 academic departments can push back the frontiers of knowledge in a complex research area: the human brain.

8 Oct 2010

Increased global attention, research needs to be given to stroke prevention: UEA

Increased global attention and research needs to be given to stroke prevention and the social and economic effects of the condition in developing countries, according to an academic at the University of East Anglia.

8 Oct 2010

FDA files complaint for permanent injunction against Brooklyn Juice Company

At the request of the U.S. Food and Drug Administration, the U.S. Department of Justice today filed a complaint for permanent injunction against a Brooklyn juice company to prevent it from processing and distributing juice products.

8 Oct 2010

Researchers unveil clues to combat enteritis in humans

The bacterium Campylobacter jejuni is a major cause of food poisoning in humans. It is normally transmitted from contaminted chicken meat, as it is frequently found in the intestines of chickens, where it apparently does not result in any symptoms. Researchers at the University of Veterinary Medicine, Vienna have now solved the puzzle, showing that Campylobacter can survive ambient oxygen levels thanks to the presence of other bacteria, species of Pseudomonas.

7 Oct 2010

Paralysis News and Research

Further Reading

Research suggests targeting spleen may promote healing of spinal cord injury

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

U.N. agencies, Rotary International launch mass polio immunization campaign in Central Africa

GPI launches new advocacy coalition to advance embryonic stem cell research in U.S.

Collapsing with laughter: Literally

Clear guidelines needed for consistent diagnosis and treatment of childhood stroke

Scientists develop new method to analyze early detection of virus

Athletic performance can improve after heat acclimation

Salk discovers potential new target for MS

Nanotope enters agreement with Smith & Nephew to develop cartilage regeneration product

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

'Keyhole' procedure safer than invasive approaches in removing acoustic neuroma without hearing loss

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

FDA designates NeuRx Diaphragm Pacing System as HUD device for ALS patients

Two-day symposium marks an extraordinary decade for Brown Institute for Brain Science

Increased global attention, research needs to be given to stroke prevention: UEA

FDA files complaint for permanent injunction against Brooklyn Juice Company

Researchers unveil clues to combat enteritis in humans

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News